TY - JOUR
T1 - Local control and toxicity after magnetic resonance imaging (MR)-guided single fraction lung stereotactic ablative radiotherapy
AU - Tekatli, Hilâl
AU - Palacios, Miguel A.
AU - Schneiders, Famke L.
AU - Haasbeek, Cornelis J. A.
AU - Slotman, Ben J.
AU - Lagerwaard, Frank J.
AU - Senan, Suresh
N1 - Funding Information: H.T., C.J.H., and M.A.P. have declared no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. F.L.S. has received honoraria from ViewRay. B.J.S., F.J.L., and S.S. have received honoraria and departmental research funding from ViewRay, and received departmental research funding from Varian Medical Systems. Publisher Copyright: © 2023 The Author(s)
PY - 2023/10/1
Y1 - 2023/10/1
N2 - Purpose: Magnetic resonance imaging (MR)-guided radiotherapy permits continuous intrafraction visualization and use of automatic triggered beam delivery, with use of smaller planning target volumes (PTV). We report on long-term clinical outcomes following MR-guided single fraction (SF) lung SABR on a 0.35 T linac. Materials and Methods: Details of patients treated with SF-SABR for lung tumors were accessed from an ethics approved institutional database. A breath-hold 3D MR simulation scan was performed using a true FISP sequence, followed by a breath-hold 3D CT scan. The gross tumor volume (GTV) was first contoured on the breath-hold CT scan, which was then compared with contours on the 3D MR scan, before the GTV was finalized. SABR plans used step-and-shoot IMRT beams to a PTV derived by adding a 5 mm margin to the breath-hold GTV, and a 3 mm gating window was used. SABR was delivered during repeated breath-holds, using automatic beam gating with continuous visualization of the GTV in a sagittal MR plane. Results: Between 2018–2022, 50 consecutive patients were treated, and 69% had a primary non-small cell lung cancer. Median PTV was 11.2 cc (range 3.9–53.5); 80% of GTV's were located ≤2.5 cm from the chest wall. Prescribed doses were 34 Gy (in 58%), 30 Gy (32%), or between 20–28 Gy (10%). After a median follow-up of 18.1 months (95% CI 12.8–23.5), the 2-year survival was 82% (89% for primary NSCLC and 62% for metastases). After a median follow-up of 16.1 months (95% CI 11.2–21.1), local recurrences developed in 2 patients (4%). The 3-year local control rate was 97%, and just 1 patient developed grade ≥3 toxicity (chest wall pain). Conclusion: MR-guided SF-SABR delivery to lung tumors on a 0.35 T linac, using repeated breath-holds with automatic beam gating, achieves good tumor control and low toxicity.
AB - Purpose: Magnetic resonance imaging (MR)-guided radiotherapy permits continuous intrafraction visualization and use of automatic triggered beam delivery, with use of smaller planning target volumes (PTV). We report on long-term clinical outcomes following MR-guided single fraction (SF) lung SABR on a 0.35 T linac. Materials and Methods: Details of patients treated with SF-SABR for lung tumors were accessed from an ethics approved institutional database. A breath-hold 3D MR simulation scan was performed using a true FISP sequence, followed by a breath-hold 3D CT scan. The gross tumor volume (GTV) was first contoured on the breath-hold CT scan, which was then compared with contours on the 3D MR scan, before the GTV was finalized. SABR plans used step-and-shoot IMRT beams to a PTV derived by adding a 5 mm margin to the breath-hold GTV, and a 3 mm gating window was used. SABR was delivered during repeated breath-holds, using automatic beam gating with continuous visualization of the GTV in a sagittal MR plane. Results: Between 2018–2022, 50 consecutive patients were treated, and 69% had a primary non-small cell lung cancer. Median PTV was 11.2 cc (range 3.9–53.5); 80% of GTV's were located ≤2.5 cm from the chest wall. Prescribed doses were 34 Gy (in 58%), 30 Gy (32%), or between 20–28 Gy (10%). After a median follow-up of 18.1 months (95% CI 12.8–23.5), the 2-year survival was 82% (89% for primary NSCLC and 62% for metastases). After a median follow-up of 16.1 months (95% CI 11.2–21.1), local recurrences developed in 2 patients (4%). The 3-year local control rate was 97%, and just 1 patient developed grade ≥3 toxicity (chest wall pain). Conclusion: MR-guided SF-SABR delivery to lung tumors on a 0.35 T linac, using repeated breath-holds with automatic beam gating, achieves good tumor control and low toxicity.
KW - Gated delivery
KW - Lung cancer
KW - MR-guided online adaptive SABR
KW - Single fraction
KW - Stereotactic ablative radiotherapy
KW - Toxicity
UR - http://www.scopus.com/inward/record.url?scp=85166756293&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.radonc.2023.109823
DO - https://doi.org/10.1016/j.radonc.2023.109823
M3 - Article
C2 - 37516364
SN - 0167-8140
VL - 187
JO - Radiotherapy and oncology
JF - Radiotherapy and oncology
M1 - 109823
ER -